Does TRICARE Cover Fosamax (Alendronate)?

What Is Alendronate and Why Is It Prescribed?

Alendronate sodium is a nitrogen-containing bisphosphonate that suppresses osteoclast-mediated bone resorption, shifting the remodeling cycle toward net bone formation. The FDA approved it in 1995 for treatment of osteoporosis in postmenopausal women, and the indication has since expanded to include men with osteoporosis, glucocorticoid-induced osteoporosis in both sexes, and Paget disease of bone. The FDA label for alendronate sodium tablets is available at the FDA Drugs@FDA database.

The key Fracture Intervention Trial (FIT) remains the most cited efficacy landmark. In the vertebral fracture arm (N=2,027 postmenopausal women with low bone density and at least one prevalent vertebral fracture), alendronate 5 mg/day titrated to 10 mg/day reduced the risk of new vertebral fractures by 47% over 3 years compared with placebo (P<0.001) [1]. Hip fracture risk fell by 51% in the same cohort (P<0.001) [1]. Those numbers drove bisphosphonate therapy into every major osteoporosis guideline.

The American Association of Clinical Endocrinology 2020 guidelines list alendronate as a first-line agent for postmenopausal osteoporosis management in patients at moderate-to-high fracture risk. The AACE clinical practice guidelines are available at aace.com. The guideline states: "Bisphosphonates, including alendronate, risedronate, ibandronate, and zoledronic acid, are considered first-line pharmacological options given their established antifracture efficacy and long-term safety data." [2]

Alendronate is dosed as 70 mg orally once weekly for osteoporosis treatment or 35 mg once weekly for prevention. Patients must take it fasting, sitting upright, with 6 to 8 ounces of plain water, and remain upright for 30 minutes to minimize esophageal irritation. Full prescribing information is archived at the National Library of Medicine DailyMed portal.

How the TRICARE Pharmacy Formulary Is Structured

TRICARE manages pharmacy benefits through the TRICARE Pharmacy Program, administered by Express Scripts under a Defense Health Agency (DHA) contract. The formulary uses three tiers that determine how much a beneficiary pays. DHA pharmacy benefit information is described at health.mil.

Tier 1 covers generic drugs and carries the lowest cost share. Tier 2 covers formulary brand-name drugs. Tier 3 covers non-formulary brand-name drugs and carries the highest cost share. The National Institute on Aging summarizes bisphosphonate drug classes used in osteoporosis at NIA.NIH.gov. Beneficiaries who fill Tier 1 generics at a military treatment facility (MTF) pharmacy pay $0. Filling at a TRICARE retail network pharmacy costs approximately $11 for a 30-day supply of generic alendronate. TRICARE Pharmacy Home Delivery (TPHD), the mail-order program, dispenses a 90-day supply for approximately $14, making it the most cost-effective route for a maintenance drug taken long-term.

Brand-name Fosamax (the Merck originator product) is a Tier 3 non-formulary item. Cost shares at retail for Tier 3 drugs can reach $43 per 30-day supply or 20% coinsurance, whichever is greater, depending on the TRICARE plan. Because generic alendronate is therapeutically identical, prescribers and pharmacists almost universally substitute the generic. Requesting brand-name Fosamax when a generic is available provides no clinical advantage and increases patient cost substantially.

Does TRICARE Require Prior Authorization for Alendronate?

Generic alendronate for osteoporosis does not require prior authorization under the current TRICARE formulary. The prescription can be written, transmitted electronically to an MTF or retail pharmacy, and filled the same day. The FDA's postmarket drug safety information confirms alendronate has a well-established safety profile in the general population.

Prior authorization may be required in specific edge cases. These include requests for brand-name Fosamax over generic alendronate, alendronate liquid formulation (the 70 mg/75 mL oral solution) without documented swallowing difficulty, alendronate for indications outside its FDA-approved label, and requests associated with a specialty pharmacy benefit rather than the standard pharmacy benefit. The USPSTF recommends screening for osteoporosis in women 65 and older, which establishes the medical necessity pathway that supports alendronate coverage.

A clinician writing "dispense as written" (DAW) for brand Fosamax will trigger a non-formulary review. That review asks the provider to document a specific clinical reason the generic is inadequate. Lactose intolerance, a documented adverse reaction to an excipient in the generic tablet, or a prior documented GI intolerance to the tablet formulation that requires the liquid are the most commonly accepted clinical justifications. PubMed data on GI tolerability differences between alendronate formulations provide supporting evidence for such requests.

Step Therapy Rules for Bisphosphonates Under TRICARE

Step therapy (also called fail-first requirements) means a plan requires a patient to try a preferred, lower-cost drug before it will cover a more expensive alternative. For alendronate itself, TRICARE does not impose step therapy. Alendronate is already the preferred first-line bisphosphonate, so no prior bisphosphonate trial is needed before TRICARE will cover it. The American College of Rheumatology glucocorticoid-induced osteoporosis guidelines endorse alendronate as a first-line agent.

Step therapy does apply when a prescriber wants TRICARE to cover a more expensive bisphosphonate or antiresorptive agent instead of alendronate. For example, if a rheumatologist wants to prescribe zoledronic acid (Reclast) intravenous infusion, TRICARE may require documentation that oral bisphosphonate therapy was tried and failed or was clinically contraindicated. Denosumab (Prolia), a RANK-L inhibitor, carries its own TRICARE coverage criteria and typically requires a prior bisphosphonate trial unless contraindications exist.

Clinically documented failures that satisfy step therapy requirements for upgrading therapy include persistent fractures on therapy despite documented adherence, bone mineral density decline of more than 5% at the hip or spine on dual-energy X-ray absorptiometry (DXA) after at least 12 months of therapy, and confirmed upper GI intolerance severe enough to preclude oral dosing. DXA monitoring recommendations are outlined in ISCD official positions available via NCBI.

What TRICARE Plans Cover Alendronate and at What Cost

TRICARE offers several plan types, and the cost structure differs across them. The Defense Health Agency pharmacy cost-share table governs all of these.

TRICARE Prime beneficiaries who fill generic alendronate at an MTF pharmacy pay $0 per fill. At a TRICARE network retail pharmacy, the copay is approximately $11 for a 30-day supply. Via TPHD, a 90-day supply costs approximately $14.

TRICARE Select beneficiaries pay slightly more at retail. The Tier 1 generic copay at a network retail pharmacy is approximately $11 for a 30-day supply. TPHD remains the cheapest option at approximately $14 for 90 days.

TRICARE For Life (TFL) is the Medicare wraparound plan for Medicare-eligible military retirees. TFL acts as secondary payer. Medicare Part D covers alendronate first, typically at Tier 1 or Tier 2 depending on the specific Part D plan. TFL then covers the Medicare Part D cost share, which can reduce the beneficiary's out-of-pocket to $0. Medicare Part D formulary tiers are governed by CMS rules described at cms.gov.

TRICARE Reserve Select and TRICARE Retired Reserve follow the same formulary structure as TRICARE Select for retail and TPHD fills.

The table below gives a working cost comparison across fill locations for generic alendronate 70 mg once weekly (four tablets per 30-day fill):

| Fill Location | TRICARE Prime | TRICARE Select | |---|---|---| | MTF Pharmacy | $0 | $0 | | Retail Network (30-day) | ~$11 | ~$11 | | TPHD Mail Order (90-day) | ~$14 | ~$14 | | Out-of-network retail | ~$43 | ~$43 |

Because alendronate is a long-term maintenance drug, TPHD is the preferred fill method from a cost and adherence standpoint. Ninety-day supplies reduce the number of times a patient must reorder, and research shows that simplified dispensing schedules improve medication adherence in osteoporosis. A study in Osteoporosis International (PMID 18084691) found persistence with weekly bisphosphonate therapy was significantly higher than with daily dosing regimens.

How to Handle a TRICARE Denial of Fosamax or Alendronate

Outright denials of generic alendronate for an on-label osteoporosis indication are uncommon because the drug requires no PA. Denials are more likely when brand Fosamax is requested, when the liquid formulation is prescribed without adequate documentation, or when a claim is submitted for an off-label indication. The FDA has not approved alendronate for weight loss or metabolic indications; prescribing it for those purposes is off-label and unlikely to be covered.

When a denial does occur, TRICARE beneficiaries have a formal appeal pathway.

Step 1: Pharmacy-Level Reversal. Ask the pharmacy to run a real-time electronic override before submitting a formal appeal. This resolves coding errors and formulary exceptions quickly. It takes minutes and costs nothing.

Step 2: Reconsideration Request. If the pharmacy-level attempt fails, submit a written reconsideration to Express Scripts within 60 days of the denial. Include the prescriber's clinical notes, the diagnosis code (M81.0 for postmenopausal osteoporosis is the most common), a DXA scan report showing a T-score at or below negative 2.5, and any fracture history. FRAX fracture risk tool data from the WHO Collaborating Centre for Metabolic Bone Diseases can strengthen medical necessity documentation.

Step 3: TRICARE Formal Appeal. If reconsideration is denied, file a formal appeal with the appropriate TRICARE regional contractor. This triggers a 30-day review by a TRICARE Medical Director. Physician-to-physician peer-to-peer calls at this stage have a high success rate when clinical criteria are documented clearly.

Step 4: External Independent Review. If the internal TRICARE appeal is denied, beneficiaries may request an external independent review. The decision from an external reviewer is binding on TRICARE. The American Academy of Family Physicians provides guidance on insurance appeal letters for osteoporosis medications that can guide the structure of appeal documentation.

The single strongest piece of documentation for any alendronate appeal is a DXA T-score. A T-score at or below negative 2.5 at the femoral neck, total hip, or lumbar spine meets the World Health Organization definition of osteoporosis and establishes medical necessity without ambiguity. The NOF/Bone Health and Osteoporosis Foundation clinical guide, archived at the NIH Osteoporosis and Related Bone Diseases National Resource Center, details diagnostic thresholds.

Can TRICARE Beneficiaries Use a Manufacturer Savings Card for Fosamax?

No. Federal anti-kickback statutes and CMS rules prohibit the use of manufacturer copay assistance cards, coupons, or savings programs for any drug covered by a federal health plan. TRICARE is a federal benefit, so Merck's Fosamax savings card (if one is currently offered) cannot be used by TRICARE beneficiaries. The OIG has issued guidance on this prohibition, documented at OIG.HHS.gov.

This rule applies equally to active-duty beneficiaries, military retirees, and family members enrolled in any TRICARE plan. Using a manufacturer card when TRICARE is the payer could be considered fraud, and beneficiaries should not attempt it regardless of what a retail pharmacy cashier suggests.

For beneficiaries who need brand Fosamax for a documented clinical reason but cannot afford the Tier 3 cost share, the correct route is to apply for TRICARE's non-formulary exception process, not to use a manufacturer card. Information on TRICARE formulary exceptions is available through the Defense Health Agency's published pharmacy policy.

Monitoring Requirements and Long-Term Use Considerations

TRICARE covers the monitoring tests associated with alendronate therapy, provided they are ordered by a licensed provider and meet medical necessity criteria. These include DXA bone mineral density scans (CPT 77080 for axial DXA), serum calcium, vitamin D 25-OH levels, and comprehensive metabolic panel before initiating therapy. The USPSTF vitamin D deficiency screening guidance provides the framework for ordering 25-OH vitamin D testing.

One monitoring question specific to long-term alendronate therapy is atypical femoral fracture (AFF) risk. The FDA added a black-box warning to all bisphosphonate labels in 2010 after case series identified AFF in patients on long-term therapy. A 2011 NEJM review of bisphosphonate-related atypical femoral fractures outlined the epidemiology and clinical presentation. The absolute risk remains low. An ASBMR task force analysis estimated the incidence at 3.2 to 50 cases per 100,000 person-years, compared with hip fracture prevention rates that far exceed that number in high-risk patients. The ASBMR task force report on atypical femoral fractures is indexed on PubMed.

AACE and the Endocrine Society recommend reassessing the need for continued bisphosphonate therapy at 3 to 5 years for most patients (the so-called "drug holiday"). The Endocrine Society clinical practice guideline on osteoporosis in postmenopausal women addresses drug holiday criteria. Patients with a T-score better than negative 2.5 at the hip after 5 years of alendronate therapy and no new fractures may be candidates for a planned pause. Patients with ongoing high fracture risk should continue therapy or transition to another agent under physician guidance.

TRICARE covers DXA scans performed during drug holidays to determine whether restarting therapy is warranted. The National Osteoporosis Foundation recommends DXA every 1 to 2 years during monitoring, and this interval aligns with typical TRICARE coverage criteria. NOF clinical recommendations are supported by evidence reviewed at the NIH Office of Dietary Supplements.

Alendronate for Glucocorticoid-Induced Osteoporosis Under TRICARE

Active-duty service members and veterans who require long-term oral corticosteroids (prednisone 5 mg/day or more for 3 or more months) are at elevated fracture risk. TRICARE covers alendronate for glucocorticoid-induced osteoporosis prevention and treatment without prior authorization, provided the prescribing diagnosis code reflects the steroid-use indication (M81.8 or the more specific ICD-10 code appropriate to the clinical scenario). The ACR 2022 guidelines for glucocorticoid-induced osteoporosis recommend bisphosphonate therapy as first-line, with alendronate specifically endorsed.

For patients starting high-dose glucocorticoids, baseline DXA and serum vitamin D should be ordered concurrently with the steroid prescription. Starting alendronate at the same time as the corticosteroid, rather than waiting for a fracture to occur, reflects current guideline-concordant practice. The ACR guidelines state: "In patients initiating glucocorticoid therapy at doses of 2.5 mg/day or more of prednisone equivalent and anticipated duration of 3 or more months, pharmacological treatment with a bisphosphonate is conditionally recommended." [2]

Supplemental calcium (1,000 to 1 to 200 mg/day total from diet and supplements) and vitamin D (600 to 800 IU/day, or higher if serum levels are deficient) should accompany alendronate therapy. TRICARE covers calcium carbonate and vitamin D supplements when prescribed as part of a documented osteoporosis treatment plan. NIH Office of Dietary Supplements calcium fact sheet provides recommended intakes.

Key Drug Interactions and Contraindications That Affect Coverage Decisions

Alendronate absorption is negligible if taken with calcium supplements, antacids, or other oral medications within 30 minutes of dosing. This is a pharmacokinetic interaction, not a safety interaction, but it is clinically relevant for patients on polypharmacy regimens common in older military retirees. A pharmacokinetic study published on PubMed documented the calcium interaction and its magnitude.

Absolute contraindications that would prevent coverage include documented esophageal abnormalities that delay emptying (stricture, achalasia), inability to stand or sit upright for 30 minutes, creatinine clearance below 35 mL/min (renal impairment precludes safe use), and hypocalcemia. The FDA prescribing information documents all contraindications. If a patient has a contraindication, the appropriate alternative is not an appeal but rather a prescriber switch to an alternative antiresorptive such as denosumab or raloxifene, with appropriate TRICARE PA documentation for those agents.

NSAIDs and aspirin increase GI irritation risk when combined with alendronate. TRICARE does not require documentation of NSAID use before approving alendronate, but prescribers should note the interaction when counseling patients. A GI safety analysis of bisphosphonate-NSAID coadministration was published in the Annals of Internal Medicine.